我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

The Neutrophil-To-Lymphocyte Ratio (NLR) and the Platelet-To- Lymphocyte Ratio (PLR) Prognostic Values in Decompensated Cirrhosis

Sana Khedher, Sahar Nasr, Rahma Ayadi, Asma Mensi and Debbesh Rathouane

Patients with decompensated cirrhosis present a state of chronic inflammation that results from an abnormal bacterial translocation and contributes to the development of circulatory dysfunction and failure.

Scoring systems such CHILD PUGH, chronic liver failure-sequential organ failure assessment (CLIF–SOFA) can help predict prognosis and consequently select patients requiring admission to intensive care unit.

Note: Decompensated cirrhosis may be a term that doctors use to explain the complications of advanced disease. People with compensated cirrhosis often do not have any symptoms because their liver remains properly functioning. Later liver function reduces, it can become decompensated cirrhosis. Decompensated cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal haemorrhage.

Clinical trial data demonstrate that within the population of persons with decompensated cirrhosis, most patients receiving direct-acting antiviral (DAA) therapy experience improvement in clinical and biochemical indicators of disease between baseline and post treatment week twelve, includes patients with CTP a class C cirrhosis. Real-world data comparing DAA response rates demonstrate that patients with cirrhosis and hepatoma (HCC) have lower SVR rates than cirrhotics without HCC (Prenner, 2017); (Beste, 2017). In a large VA study including sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ ombitasvir plus dasabuvir regimens (with and without ribavirin), overall SVR rates were 91% in patients without HCC versus 74% in those with HCC (Beste, 2017). After adjusting for confounders, the presence of HCC was associated with a lower likelihood of SVR (AOR=0.38). Whether this lower SVR are often overcome with an extended duration of therapy is unknown.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。